About this Research Topic
The respiratory tract is constantly exposed to potentially pathogenic microorganisms, including viruses. The most representative human respiratory viruses are influenza, rhinovirus, respiratory syncytial virus and coronaviruses. Viral clearance and the resolution of infection require a complex response initiated by immune cells. Several factors can contribute to the development of a protective immune response against viral infections, including the host microbiota.
The microbiota consists of a large number of microorganisms including bacteria, viruses, protozoa and fungi, which colonize the human body and establish important interactions with human cells. Recent studies indicate that the microbiota is relevant for the respiratory health playing a protective role during respiratory viral infections. This crosstalk between lung, gut and immunity contributes to the maintenance of the pulmonary homeostasis and is known as the gut-lung axis. However, the mechanisms involved in these interactions are not totally clear.
In this collection, we aim to address the role of lung and/or gut microbiota and its influence on innate and adaptive immune responses against respiratory viral infections. The microbiota dysbiosis can lead to long-term consequences on inflammatory conditions. Although it is known that the microbiota provides local and systemic signals to control the innate and adaptive immune responses, these interactions are not fully understood during respiratory viral infections. The ultimate goal of this Research Topic is to better understand the mechanisms underlying the interactions between gut and/or lung microbiota and the immune response during respiratory viral infections to help the development of future interventions or improve current interventions, such as vaccines or immunotherapy against respiratory viruses.
We seek Original Research, Review, Mini-Review, Hypothesis and Theory, Perspective, Clinical Trial, Case Report and Opinion articles that cover, but are not limited to, the following topics:
• The role of the virome during respiratory viral infections
• Lung or gut microbiota modulation of the immune response against respiratory virus infections
• Microbiota and its metabolites as interventions to induce a protective immune response against respiratory viruses
• Importance of the microbiota during vaccine response against respiratory viruses
• Age contribution to microbiota diversity and immune response against respiratory virus infection
• Lung or gut dysbiosis associated with respiratory viral infections
Topic Editor Ana Paula Duarte de Souza receives project funding by OM Pharma Ltd, related to the development of therapeutics for respiratory infections. The other Topic Editors declare no competing interests.
The microbiota consists of a large number of microorganisms including bacteria, viruses, protozoa and fungi, which colonize the human body and establish important interactions with human cells. Recent studies indicate that the microbiota is relevant for the respiratory health playing a protective role during respiratory viral infections. This crosstalk between lung, gut and immunity contributes to the maintenance of the pulmonary homeostasis and is known as the gut-lung axis. However, the mechanisms involved in these interactions are not totally clear.
In this collection, we aim to address the role of lung and/or gut microbiota and its influence on innate and adaptive immune responses against respiratory viral infections. The microbiota dysbiosis can lead to long-term consequences on inflammatory conditions. Although it is known that the microbiota provides local and systemic signals to control the innate and adaptive immune responses, these interactions are not fully understood during respiratory viral infections. The ultimate goal of this Research Topic is to better understand the mechanisms underlying the interactions between gut and/or lung microbiota and the immune response during respiratory viral infections to help the development of future interventions or improve current interventions, such as vaccines or immunotherapy against respiratory viruses.
We seek Original Research, Review, Mini-Review, Hypothesis and Theory, Perspective, Clinical Trial, Case Report and Opinion articles that cover, but are not limited to, the following topics:
• The role of the virome during respiratory viral infections
• Lung or gut microbiota modulation of the immune response against respiratory virus infections
• Microbiota and its metabolites as interventions to induce a protective immune response against respiratory viruses
• Importance of the microbiota during vaccine response against respiratory viruses
• Age contribution to microbiota diversity and immune response against respiratory virus infection
• Lung or gut dysbiosis associated with respiratory viral infections
Topic Editor Ana Paula Duarte de Souza receives project funding by OM Pharma Ltd, related to the development of therapeutics for respiratory infections. The other Topic Editors declare no competing interests.
Keywords: respiratory viral infection, lung microbiota, gut microbiota, virome
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
